Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Detailed price information for Engene Holdings Inc (ENGN-Q) from The Globe and Mail including charting and trades.

Coherus Oncology (NASDAQ:CHRS) executives said the company has moved quickly through a multi-year transformation toward ...

U.S Department of Justice settles monopoly lawsuit against Live Nation. Some states are continuing separate action; Iowa ...

Definium Therapeutics' lead asset, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder. The company is preparing for potential commercialization by building ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the ...

Live Nation Entertainment settled with the U.S. Justice Department in the middle of a trial on claims ​the Ticketmaster owner illegally dominated key parts of the live-events industry, the DOJ said on ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

Label expansion strategy -- The company is actively pursuing a broad label for Tadaraben to include all Stargardt disease patients aged 12 and older based on regulator feedback and clinical similarity ...

On the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Hendrik Scholl, Chief Medical Officer; Dr. Nathan Mata, Chief Scientific Officer; and Hao-Yuan Chuang, Belite Bio's Chief ...